ACADIA Pharmaceuticals Inc. $ACAD Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 84.0% in the first quarter, Holdings Channel reports. The firm owned 77,208 shares of the biopharmaceutical company’s stock after purchasing an additional 35,243 shares during the period. SG Americas Securities LLC’s holdings in ACADIA Pharmaceuticals were worth $1,719,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Diversified Trust Co grew its stake in ACADIA Pharmaceuticals by 12.6% during the first quarter. Diversified Trust Co now owns 44,842 shares of the biopharmaceutical company’s stock worth $998,000 after buying an additional 5,022 shares during the period. Rockefeller Capital Management L.P. grew its stake in shares of ACADIA Pharmaceuticals by 7.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,113,040 shares of the biopharmaceutical company’s stock valued at $29,729,000 after acquiring an additional 76,727 shares in the last quarter. Invesco Ltd. increased its holdings in ACADIA Pharmaceuticals by 14.5% during the 4th quarter. Invesco Ltd. now owns 847,961 shares of the biopharmaceutical company’s stock worth $22,649,000 after purchasing an additional 107,386 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth $257,000. Finally, Mackenzie Financial Corp raised its stake in shares of ACADIA Pharmaceuticals by 7.3% in the 4th quarter. Mackenzie Financial Corp now owns 57,274 shares of the biopharmaceutical company’s stock valued at $1,526,000 after purchasing an additional 3,917 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ACAD shares. Weiss Ratings lowered ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday. Bank of America upped their price target on shares of ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup raised their price target on shares of ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Finally, Canaccord Genuity Group raised their price target on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.59.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 5,401 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider directly owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 13,978 shares of company stock valued at $302,819. 26.20% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $25.97 on Friday. ACADIA Pharmaceuticals Inc. has a one year low of $19.69 and a one year high of $28.35. The company has a market capitalization of $4.45 billion, a PE ratio of 11.80, a price-to-earnings-growth ratio of 18.15 and a beta of 0.80. The stock has a fifty day moving average of $22.11 and a 200-day moving average of $23.40.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million during the quarter, compared to analyst estimates of $280.25 million. During the same quarter last year, the business earned $0.11 EPS. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.37 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.